Boston Scientific Corporation (BSX)
Market Cap | 152.13B |
Revenue (ttm) | 17.55B |
Net Income (ttm) | 2.03B |
Shares Out | 1.48B |
EPS (ttm) | 1.37 |
PE Ratio | 75.03 |
Forward PE | 34.88 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 8,239,949 |
Open | 102.96 |
Previous Close | 102.43 |
Day's Range | 102.13 - 103.24 |
52-Week Range | 71.88 - 107.17 |
Beta | 0.69 |
Analysts | Strong Buy |
Price Target | 111.64 (+8.57%) |
Earnings Date | Jul 23, 2025 |
About BSX
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates in two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention portfolios; devices ... [Read more]
Financial Performance
In 2024, Boston Scientific's revenue was $16.75 billion, an increase of 17.61% compared to the previous year's $14.24 billion. Earnings were $1.85 billion, an increase of 18.03%.
Financial StatementsAnalyst Forecast
According to 22 analysts, the average rating for BSX stock is "Strong Buy." The 12-month stock price forecast is $111.64, which is an increase of 8.57% from the latest price.
News

Boston Scientific: Old, Reliable; Buy For Their Consistent Growth
Boston Scientific is a global leader in medical devices, excelling in both MedSurg and Cardiovascular segments with consistent, industry-beating growth. Q1 2024 was a record quarter, with 21% YoY reve...

Boston Scientific Scraps This Aortic Valve, Sticks To 2025 Outlook
Boston Scientific Corporation BSX is pulling the plug on its ACURATE neo2 and Prime aortic valve systems.

Boston Scientific Corporation (BSX) Bernstein 41st Annual Strategic Decisions Conference (Transcript)
Boston Scientific Corporation (NYSE:BSX) Bernstein 41st Annual Strategic Decisions Conference Call May 28, 2025 8:01 AM ET Company Participants Michael Mahoney - Chairman and Chief Executive Officer ...

Boston Scientific to not seek US approval for heart device amid regulatory challenges
Boston Scientific said on Wednesday it will stop pursuing U.S. approval for its experimental heart device due to increased clinical and regulatory requirements.

Boston Scientific Corporation (BSX) Bank of America's 2025 Health Care Conference (Transcript)
Boston Scientific Corporation (NYSE:BSX) Bank of America's 2025 Health Care Conference May 13, 2025 11:00 AM ET Company Participants Daniel Brennan - EVP & CFO Joe Fitzgerald - EVP & Group President,...

Boston Scientific announces upcoming investor conference schedule
MARLBOROUGH, Mass. , May 1, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in two upcoming investor conferences in May.

Baron Health Care Fund Q1 2025 Top Contributors And Detractors
Boston Scientific's shares rose due to strong market growth, innovative products like pulsed field ablation, and disciplined cost management, driving double-digit EPS growth. Vertex Pharmaceuticals sa...

Second phase of ADVANTAGE AF study of FARAPULSE™ Pulsed Field Ablation System meets primary safety and efficacy endpoints
Trial achieves positive results in the treatment of persistent atrial fibrillation MARLBOROUGH, Mass. and SAN DIEGO , April 24, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today ann...

Boston Scientific Analysts Boost Their Forecasts Following Upbeat Results
Boston Scientific Corporation BSX posted better-than-expected earnings for the first quarter on Wednesday.

Boston Scientific Corporation (BSX) Q1 2025 Earnings Call Transcript
Boston Scientific Corporation (NYSE:BSX) Q1 2025 Results Conference Call April 23, 2025 8:00 AM ET Company Participants Jon Monson - Senior Vice President, Investor Relations Mike Mahoney - Chairman ...

Boston Scientific Raises Annual Outlook After Strong Heart Devices Sales In Q1, Announces CFO Transition
Boston Scientific Corporation BSX on Wednesday reported first-quarter 2025 revenues of $4.66 billion, beating the consensus estimate of $4.57 billion.

Boston Scientific Stock Surges on Strong Results, Outlook; CFO To Retire
Shares of Boston Scientific (BSX) rose sharply Wednesday after the firm posted first-quarter results that topped analysts' estimates.

Boston Scientific raises 2025 profit forecast on strong heart device sales
Boston Scientific raised its annual profit forecast after strong sales of its heart devices helped beat Wall Street expectations for first-quarter profit.

Boston Scientific Chief Financial Officer (CFO) Dan Brennan to retire; Jon Monson, senior vice president, Investor Relations to succeed Brennan
MARLBOROUGH, Mass. , April 23, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced that Dan Brennan, executive vice president and chief financial officer, has elected to ret...

Boston Scientific announces results for first quarter 2025
MARLBOROUGH, Mass. , April 23, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $4.663 billion during the first quarter of 2025, growing 20.9 percent on a reported...

Goldman Sachs Thinks These Stocks Are ‘Insulated' From a Trade War
Amdocs, Kroger, Bank of New York Mellon and Valvoline lead a list of stocks that Goldman Sachs calls “insensitive” to market volatility.

Boston Scientific announces conference call discussing first quarter 2025 results
MARLBOROUGH, Mass. , April 1, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the first quarter...

Boston Scientific Corporation (BSX) TD Cowen 45th Annual Healthcare Conference (Transcript)
Boston Scientific Corporation (NYSE:BSX) TD Cowen 45th Annual Healthcare Conference March 4, 2025 9:10 AM ET Company Participants Dan Brennan - Chief Financial Officer Ken Stein - Chief Medical Offic...

Boston Scientific announces agreement to acquire SoniVie Ltd.
Acquisition to expand Interventional Cardiology Therapies offerings with ultrasound-based renal denervation therapy for treatment of hypertension MARLBOROUGH, Mass. , March 3, 2025 /PRNewswire/ -- Bos...

Boston Scientific announces completion of €1.5 billion offering of senior notes
MARLBOROUGH, Mass. , Feb. 26, 2025 /PRNewswire/ -- Boston Scientific Corporation (the "Company") (NYSE: BSX) today announced that American Medical Systems Europe B.V.

Balloon Catheters Patent Landscape Report 2025, with Profiles of Cook Medical Technologies, Boston Scientific Scimed, Scimed Life Systems, Terumo Corp and Advanced Cardiovascular System
Dublin, Feb. 24, 2025 (GLOBE NEWSWIRE) -- The "Balloon Catheters Patent Landscape Report" has been added to ResearchAndMarkets.com's offering.

Boston Scientific announces pricing of €1.5 billion of senior notes
MARLBOROUGH, Mass. , Feb. 21, 2025 /PRNewswire/ -- Boston Scientific Corporation (the "Company") (NYSE: BSX) today announced that American Medical Systems Europe B.V.

Boston Scientific to participate in TD Cowen's 45th Annual Health Care Conference
MARLBOROUGH, Mass. , Feb. 19, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in TD Cowen's 45th Annual Health Care Conference on Tuesday, March 4, 2025.

What's Behind The 130% Rise In BSX Stock?
Boston Scientific stock (NYSE: BSX) has gained 3% in the five days since its Q4 earnings report last week. Although the company exceeded expectations with both its results and guidance, the modest sto...

Boston Scientific Corporation (BSX) Q4 2024 Earnings Call Transcript
Boston Scientific Corporation (NYSE:BSX) Q4 2024 Earnings Conference Call February 5, 2025 8:00 AM ET Company Participants Jonathan Monson - SVP, IR Michael Mahoney - Chairman and CEO Daniel Brennan ...